Radiobiological effect induced by different activities of 125I seed brachytherapy in a hepatocellular carcinoma model

被引:3
作者
Qin, Qing-Hong [1 ]
Huang, Bai-Sha [3 ]
Tan, Qi-Xing [1 ]
Yang, Wei-Ping [2 ]
Lian, Bin [1 ]
Wei, Chang-Yuan [1 ]
机构
[1] Guangxi Med Univ Tumor Hosp, Dept Breast Surg, Nanning 530021, Guangxi Provinc, Peoples R China
[2] Guangxi Med Univ Tumor Hosp, Dept Ultrasound Diag, Nanning 530021, Guangxi Provinc, Peoples R China
[3] Guangdong Women & Childrens Hosp, Dept Surg, Guangzhou, Guangdong, Peoples R China
来源
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE | 2014年 / 7卷 / 12期
关键词
I-125; seed; hepatocellular carcinoma; apoptosis; animal experimentation; DOSE-RATE BRACHYTHERAPY; INTERSTITIAL BRACHYTHERAPY; DOSIMETRIC CHARACTERISTICS; RADIATION; CANCER; RECOMMENDATIONS;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Iodine 125 (I-125) seed irradiation is an effective non-surgical treatment for unresectable hepatocellular carcinoma (HCC) patients. However, the safety and tolerability of I-125 seed sequential irradiation therapy remain unclear, there is no unified standard of brachytherapy radiation dose, and further study on the basic radiobiology of continuous rate irradiation is necessary. Methods: Forty Kunming-mice (KM-mice, China) were injected with suspensions of human hepatocellular carcinoma cells (H22) to create an animal model and mimic I-125 seed implantation. The survival rates of mice, curative effect, pathological impairments including apoptosis and necrosis were investigated. The mice were randomly divided into four groups, A, B, C and D. In group A, 0.78 mCi I-125 seeds were implanted into the tumor focus. In groups B and C, 0.58 mCi and 0.38 mCi I-125 seeds were inserted at the same location, respectively. Group D was a control group, without any treatment. After 28 days of therapy, the survival rates and the tumor size were measured, and pathological impairments was measured by light or electron microscopy. Results: The tumor volume inhibition rate was 68.21% +/- 3.21%, 51.38% +/- 4.96%, and 35.71% +/- 2.79% after 0.78 mCi, 0.58 mCi, and 0.38 mCi I-125 seeds irradiation, respectively. However, radiation-related side effects were also observed in the high-dose group. Pathological results showed that radiation effect was closely associated with radiation dose, as the increase of radiation dose, an increase in apoptosis and necrosis was detected. Significant cellular impairments were noted by pathological analysis under electron microscopy. Conclusions: Our results demonstrate that the Kunming-mouse is an ideal animal to study I-125 brachytherapy, and the curative effect was closely associated with radiation dose. High-dose of brachytherapy may effectively increase apoptosis and necrosis in liver cells in KM-mice. A dose of 0.58 mCi I-125 radioactive particles may be a safe, effective and minimally invasive therapeutic option for liver cancer.
引用
收藏
页码:5260 / 5267
页数:8
相关论文
共 50 条
  • [1] Transarterial chemoembolization with 125I seed insertion for multifocal hepatocellular carcinoma
    Wang, You-Bin
    Zhang, Ying
    Li, Peng-Fei
    Bao, Le
    Zhang, Wen-Tao
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [2] Effects of different carriers for adsorption of 125I on brachytherapy sources
    Ghahramani, M. R.
    Asgharizadeh, F.
    Assadi, M. R.
    Ahmadi, S. J.
    Moradi, K.
    IRANIAN JOURNAL OF RADIATION RESEARCH, 2012, 10 (02): : 105 - 107
  • [3] Endovascular implantation of 125I seed combined with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma
    Sun, Houbin
    Zhang, Minghui
    Liu, Ruibao
    Liu, Yan
    Hou, Yingwen
    Wu, Changjun
    FUTURE ONCOLOGY, 2018, 14 (12) : 1165 - 1176
  • [4] Development of production technology of 125I seed for brachytherapy
    Han, Hyon-Soo
    Park, Ul-Jae
    Son, Kwang-Jae
    Lee, Jun-Sig
    Hong, Soon-Bog
    Nam, Sung-Soo
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2007, 50 (5-6) : 321 - 322
  • [5] Feasibility of 125I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma
    Li, Chuanxing
    Zhang, Fujun
    Zhang, Weidong
    Zhang, Liang
    Huang, Zilin
    Wu, Peihong
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (11) : 1633 - 1640
  • [6] Synergistic Effects of 125I Seed Implantation Brachytherapy and Gemcitabine in Pancreatic Tumors
    Li, Qingcong
    Li, Yan
    Liu, Jiayu
    Huang, Xin
    Li, Zikang
    DISCOVERY MEDICINE, 2024, 36 (186) : 1464 - 1476
  • [7] Safety and efficacy of 125I brachytherapy for bilateral lung recurrences from hepatocellular carcinoma after resection or ablation
    Xiang, Zhanwang
    Bai, Mingjun
    Li, Guohong
    Zou, Bihui
    Zhong, Zhihui
    Gao, Fei
    Wu, Chun
    Huang, Mingsheng
    Zhang, Fujun
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2019, 145 (07) : 1907 - 1916
  • [8] Lobaplatin-TACE Combined with Radioactive 125I Seed Implantation for Treatment of Primary Hepatocellular Carcinoma
    Peng, Sheng
    Yang, Qiu-Xia
    Zhang, Tao
    Lu, Ming-Jian
    Yang, Guang
    Liu, Zhen-Yin
    Zhang, Rong
    Zhang, Fu-Jun
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (13) : 5155 - 5160
  • [9] Incidence and prediction of seed migration to the chest after iodine-125 brachytherapy for hepatocellular carcinoma
    Lin, Junqing
    Yang, Weizhu
    Jiang, Na
    Zheng, Qubin
    Huang, Jingyao
    Huang, Ning
    Li, Ang
    Jiang, Han
    BRACHYTHERAPY, 2017, 16 (06) : 1252 - 1256
  • [10] CT-guided 125I brachytherapy for locally recurrent nasopharyngeal carcinoma
    Yan, Huzheng
    Mo, Zhiqiang
    Xiang, Zhanwang
    Rong, Dailin
    Zhang, Yanlin
    Chen, Guanyu
    Zhong, Zhihui
    Zhang, Fujun
    Gao, Fei
    JOURNAL OF CANCER, 2017, 8 (11): : 2104 - 2113